|
1.4 BIOLOGIE - TECHNOS, MODÈLES
|
|
|
|
2.6 ETIOLOGIE - ENVIRONNEMENT
|
|
|
SlimeGate 2/7: Predatorts 3.2/4: The Predatort Victim Exchange [The Risk-Monger]
|
|
|
|
|
|
The Predatort Victim Exchange is a place where lawyers and marketing firms build up a stock of victims via mass advertising campaigns, assessing a dollar value on each individual and trading them on an open market. The best recent example of the lawyers’ victim exploitation can be seen in the explosion of Roundup victims lined up to be auctioned off to any Predatort firms with good credit at a litigation finance centre.
|
|
|
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
3.3 PRÉVENTION - VACCINS
|
|
|
|
|
Doubts raised about effectiveness of HPV vaccines [Newcastle University]
|
|
|
|
|
|
“Abnormal cell changes are likely to have been overdiagnosed in the trials because cervical cytology was conducted at 6-12 months rather than at the normal screening interval of 36 months. This means that the trials may have overestimated the efficacy of the vaccine as some of the lesions would have regressed spontaneously.”
|
|
|
|
|
|
|
|
3.5 PRÉVENTION - UV
|
|
|
|
|
4.12 BIOPSIES LIQUIDES
|
|
|
FNIH Team Selects Cancer Biomarkers in Phase I of Liquid Biopsy Reference Standards Project [Genome Web]
|
|
|
|
|
|
After officially launching the "Identification and Validation of ctDNA Quality Control Materials" Initiative last fall, a team at the Foundation of the National Institutes of Health (FNIH) has identified 14 clinically actional variants that it will incorporate as part of quality control materials to submit to the US Food and Drug Administration for eventual widespread use in circulating tumor DNA (ctDNA) testing.
|
|
|
|
|
|
|
4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS
|
|
|
|
4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
Changes in Metabolism Help Melanomas Spread [NCI]
|
|
|
|
|
|
The MCT1 inhibitor did not impair the migration of melanoma cells grown in cell culture, that is, cells grown outside of an animal in a dish. However, treating the melanoma-bearing mice with the drug significantly lowered their eventual metastatic tumor burden.
|
|
|
|
|
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
Deciphering a cancer treatment’s dark side [Science]
|
|
|
|
|
|
One common hazard of CAR-T cell therapy, as it’s known, is a dramatic inflammatory response, which can trigger symptoms from high fevers to organ failure. Research published today from a team of scientists in China seeks to untangle what’s happening at the cellular level during this response, in hopes of ultimately finding ways to prevent it.
|
|
|
|
|
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
|
|
|
|
|
|
5.2 PHARMA
|
|
|
|
|
|
5.2.5 PHARMA - GSK
|
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
5.5.5 ASCO (GASTRO-INTESTINAL)
|
|
|
|
|
|
|
6. LUTTE CONTRE LES CANCERS
|
|
|
Our best weapons against cancer are not magic bullets [Nature]
|
|
|
|
|
|
The data do make it clear that the majority of our most effective solutions will be found outside the cabinet of cutting-edge medicines. If we want to do all that we can to reduce the burden of cancer and to improve life expectancy, we must harness the tools of population statistics.
|
|
|
|
|
|